Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Cannabinoids in multiple sclerosis. Opportunity or hazard?].

Oliver Neuhaus1, Bernd C Kieseier, Ansgar Klimke

  • 1Neurologische Klinik, Heinrich-Heine-Universität, Düsseldorf. oliver.neuhaus@uni-duesseldorf.de

Der Nervenarzt
|May 25, 2004
PubMed
Summary

Cannabinoids showed no effect on spasticity scores in multiple sclerosis (MS) patients, but patient-reported pain and spasticity improved. High patient unmasking was noted in the CAMS trial.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Clinical validation of a novel in vitro diagnostic neurofilament light chain assay for the prognostication of disease activity in people with relapsing multiple sclerosis.

Multiple sclerosis (Houndmills, Basingstoke, England)·2025
Same author

AI-driven reclassification of multiple sclerosis progression.

Nature medicine·2025
Same author

Targeting the neonatal Fc receptor (FcRn) is not beneficial in an animal model of chronic neuritis.

Immunologic research·2024
Same author

Prognostic factors for worsening and improvement in multiple sclerosis using a multistate model.

Multiple sclerosis (Houndmills, Basingstoke, England)·2024
Same author

Alike but not the same: Psychological profiles of COVID-19 vaccine skeptics.

Health psychology open·2024
Same author

Temporal Relationship Between Serum Neurofilament Light Chain and Radiologic Disease Activity in Patients With Multiple Sclerosis.

Neurology·2024

Area of Science:

  • Neurology
  • Pharmacology

Context:

  • Multiple sclerosis (MS) is a chronic neurological disease characterized by spasticity and pain.
  • Cannabinoids have shown potential for symptomatic treatment in MS.
  • The CAMS study is the first phase III trial evaluating cannabinoid efficacy in MS.

Purpose:

  • To review the results of the CAMS study on cannabinoid efficacy for MS symptoms.
  • To discuss findings in the context of prior research and mechanisms of action.
  • To analyze the adverse event profile of cannabinoids in MS treatment.

Summary:

  • The CAMS study, a randomized placebo-controlled trial, found no significant effect of cannabinoids on the primary outcome of spasticity reduction (Ashworth score).
  • However, patient-reported outcomes indicated significant improvements in spasticity and pain.

Related Experiment Videos

  • A notable limitation was high patient unmasking in the active treatment group.

    • Impact:

    • The findings contribute to understanding cannabinoid therapy for multiple sclerosis symptoms.
    • Highlights the discrepancy between objective measures and patient-reported outcomes.
    • Informs future research on cannabinoid use and trial design in MS.